LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 2 | B12 | 72 | hr | 1235 | 4514 | 4277 | 1.0553 | 1.0610 |
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 1235 | 4828 | 4583 | 1.0534 | 1.0558 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 1235 | 4201 | 4355 | 0.9644 | 0.9605 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 1235 | 4400 | 4277 | 1.0287 | 1.0318 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 1235 | 5106 | 4583 | 1.1140 | 1.1175 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 1235 | 4389 | 4355 | 1.0076 | 1.0083 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 1235 | 4157 | 4277 | 0.9719 | 0.9684 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 1235 | 4765 | 4583 | 1.0396 | 1.0415 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 1235 | 4340 | 4355 | 0.9963 | 0.9960 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 1235 | 4485 | 4277 | 1.0485 | 1.0536 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 1235 | 5098 | 4583 | 1.1123 | 1.1158 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1235 | 4425 | 4355 | 1.0159 | 1.0174 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1235 | 4195 | 4277 | 0.9808 | 0.9784 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1235 | 4873 | 4583 | 1.0632 | 1.0659 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 1 | B07 | 72 | hr | 1235 | 3699 | 4355 | 0.8492 | 0.8280 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 2 | B07 | 72 | hr | 1235 | 3551 | 4277 | 0.8302 | 0.8026 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 3 | B07 | 72 | hr | 1235 | 4209 | 4583 | 0.9183 | 0.9119 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1235 | 4427 | 4474 | 0.9893 | 0.9885 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1235 | 4664 | 4578 | 1.0187 | 1.0197 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1235 | 4996 | 4929 | 1.0135 | 1.0135 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 1235 | 4023 | 4474 | 0.8991 | 0.8886 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 1235 | 4772 | 4578 | 1.0422 | 1.0443 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 1235 | 4816 | 4929 | 0.9770 | 0.9768 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 1235 | 4364 | 4474 | 0.9753 | 0.9732 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 2 | I10 | 72 | hr | 1235 | 1 | 4578 | 0.0002 | -0.9769 |